Reuters Events | Pharma

Thought leadership and innovation for the Pharmaceutical Industry

I'm excited to be able to unveil Reuters Events Pharma's latest report, conducted with EY, into the impacts of the 2020 pandemic on US life sciences businesses and its future implications for the industry.

 

Following on from our earlier report into the impacts for the sector in Europe, the US survey captures the views of more than 550 life sciences leaders there along with our analysis of the findings.

 

The report documents the way the sector adapted rapidly to the sudden challenges of a locked down world and outlines the pandemic’s deep impact. It has forced HCPs to work under great pressure and in radically different ways, obliging Commercial and Medical Affairs teams to fundamentally rethink how they engage. Patient teams, meanwhile, find themselves in sudden demand in a remote setting and R&D are trying to work out what the post-pandemic impacts will be on trials.

 

Digital has become a central part of the adjustment to these new realities and this process of adaptation has already begun. As the report details, life sciences companies are increasing investments en-masse into digital customer engagement.

 

While almost every pharma business was already somewhere on this innovation and transformation journey before 2020, the imperative to adapt is now urgent.

 

Pharma leaders have the unenviable task of investing today for a very uncertain tomorrow.

 

We hope this report serves to provide insights that will help navigate the risks and to capture the opportunities

that lie ahead. 

 

 

Blair Gottscho, Managing Director, Reuters Events Pharma